Use of Resource Modeling to Quantify the Organizational Impact of Subcutaneous Formulations for the Treatment of Oncologic Patients: The Case of Daratumumab in Multiple Myeloma-Reference-Cited by-同舟云学术

Use of Resource Modeling to Quantify the Organizational Impact of Subcutaneous Formulations for the Treatment of Oncologic Patients: The Case of Daratumumab in Multiple Myeloma

Published:2022-11 Issue:11 Volume:44 Page:1480-1493
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Federici Carlo^ORCID,Rognoni Carla,Costa Francesco,Armeni Patrizio,Crovato Elisa,Bellucci Stefania

Funder

Cilag

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference27 articles.

1. Applying dynamic simulation modeling methods in health care delivery research—the SIMULATE checklist: report of the ISPOR simulation modeling emerging good practices task force;Marshall;Value Health J Int Soc Pharmacoeconomics Outcomes Res,2015

2. HTA Core Model [EuNetHTA website]. Available at: https://www.eunethta.eu/hta-core-model, approximately May 2021.

3. Resource modelling: the missing piece of the HTA jigsaw?;Thokala;PharmacoEconomics,2015

4. Reorganizing patient care and workflow in the operating room: a cost-effectiveness study;Stahl;Surgery,2006

5. Capacity constraints and cost-effectiveness: a discrete event simulation for drug-eluting stents;Jahn;Med Decis Making,2010

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial);JCO Oncology Practice;2024-07-19

2. Improved efficiency of daratumumab treatment of multiple myeloma adopting the subcutaneous route: A micro‐costing analysis in three Italian hematology centers;Cancer Medicine;2023-11-09